Revista Española de Medicina Nuclear e Imagen Molecular, published by Elsevier España SLU, stands as a vital resource in the field of Radiology, Nuclear Medicine, and Molecular Imaging. With an ISSN of 2253-654X, this journal is committed to disseminating high-quality research and advancements in clinical practices, aiming to bridge the gap between theoretical research and application in healthcare. Operating since 2012, it features a robust archive of peer-reviewed articles and case studies, although it currently holds a Q4 ranking in the Scopus category, indicating significant potential for growth and influence within the academic community. The journal is indexed in Scopus, with a rank of 255 out of 333, placing it in the 23rd percentile, which underlines the need for increased contributions from researchers eager to enhance its standing. While it is not an open-access journal, its availability through libraries and institutions ensures that a wide audience can access critical findings and innovations in the rapidly evolving field of nuclear medicine. As we look towards the convergence period from 2012 to 2024, Revista Española de Medicina Nuclear e Imagen Molecular aspires to fortify its role as a cornerstone for collaboration and advancement in nuclear imaging and radiology.

Radiology-Imaging Cancer is a prestigious journal published by the Radiological Society of North America (RSNA), focusing on the critical intersection of radiology, oncology, and advanced imaging techniques. This journal stands out in its field with a commendable ranking in the Q2 category for Medicine (miscellaneous) and Oncology, and an impressive Q1 ranking in Radiology, Nuclear Medicine and Imaging, according to the 2023 quartiles. With an ISSN of 2638-616X, it serves as an essential platform for the dissemination of research that contributes to the understanding and improvement of cancer diagnosis and treatment. Its comprehensive scope encompasses a range of topics, from innovative imaging modalities to clinical applications in oncology, making it a valuable resource for researchers, clinicians, and students interested in the evolving field of cancer imaging. Despite being published in the United States, the journal aims for a global reach, catering to a wide audience dedicated to advancing medical science.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging, published by Edizioni Minerva Medica in Italy, serves as a pivotal platform for researchers and practitioners in the fields of Nuclear Medicine and Molecular Imaging. With an ISSN of 1824-4785 and an E-ISSN of 1827-1936, this journal boasts a respectable impact factor and is positioned in the Q3 quartile of the Radiology, Nuclear Medicine and Imaging category, based on the latest 2023 evaluations. As the journal continues to converge from its inception in 2004 to its anticipated expansions through 2024, it aims to disseminate high-quality, peer-reviewed articles that advance the frontier of imaging technologies and their applications in clinical practice. Researchers, professionals, and students are encouraged to contribute to its diverse scope, which encompasses innovative research, clinical findings, and reviews that encapsulate cutting-edge advancements in the field, highlighting its importance as an essential resource for knowledge and collaboration.

Nuclear Medicine and Molecular Imaging, published by SPRINGER HEIDELBERG, stands as a pivotal platform in the interdisciplinary field of radiology and nuclear medicine, focusing on innovative research and developments from 2010 to 2024. With its ISSN 1869-3474 and E-ISSN 1869-3482, this journal aims to disseminate advanced studies that explore the diagnostic and therapeutic applications of nuclear medicine technologies. Operating from Germany, it has positioned itself in the Q3 category within the Radiology, Nuclear Medicine and Imaging sector, showcasing its relevance among peer journals, with a Scopus rank of #204 out of 333. This journal not only serves as an essential resource for researchers and practitioners eager to stay abreast of modern methodologies and findings but also underscores the crucial advancements in molecular imaging techniques. Although currently not an open-access journal, it doesn't detract from its mission to promote knowledge exchange among academia and the medical community, thus paving the way for innovative solutions and improved patient care in nuclear medicine.

Tomography is an esteemed peer-reviewed journal published by MDPI, focusing on a broad spectrum of topics related to medical imaging and diagnostics. Launched in 2015, this Open Access journal serves as a vital platform for researchers, professionals, and students in the fields of medicine, radiology, nuclear medicine, and imaging. With an impressive impact factor reflecting its relevance, the journal has achieved a quartile ranking of Q2 in both Medicine (Miscellaneous) and Radiology, Nuclear Medicine, and Imaging as of 2023. Renowned for disseminating high-quality research, Tomography welcomes original research articles, reviews, and technical notes, fostering innovation and collaboration within the scientific community. Housed in Basel, Switzerland, the journal aims to bridge the gap between fundamental research and clinical application, appealing to a diverse readership eager to advance the field of medical imaging.

The American Journal of Nuclear Medicine and Molecular Imaging (ISSN: 2160-8407), published by E-CENTURY PUBLISHING CORP, is a distinguished platform for the dissemination of cutting-edge research in the fields of nuclear medicine and molecular imaging. With a commitment to advancing scientific inquiry and clinical applications, this journal serves as a vital resource for researchers, clinicians, and students dedicated to exploring innovative imaging modalities, radiopharmaceuticals, and their applications in diagnosing and treating various medical conditions. Although currently not available as an open-access journal, this publication plays a crucial role in fostering academic dialogue and collaboration within the medical community. Its diverse range of topics and expert contributions underscore its impact in bridging the gap between research findings and clinical practice, making it an essential read for anyone interested in the rapidly evolving landscape of nuclear medicine and imaging technologies.

ANNALS OF NUCLEAR MEDICINE is a prominent academic journal dedicated to the field of nuclear medicine, published by Springer. With a rich publication history dating back to 1987 and continuing through 2024, this journal serves as a vital resource for researchers and practitioners interested in the latest developments in nuclear imaging, radiopharmaceuticals, and therapeutic applications. Ranked in the second quartile (Q2) for both Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging categories in 2023, it maintains a strong position in the academic community, with an impressive Scopus rank of #104 out of 333 in its field, placing it in the 68th percentile. The journal is not open access but offers a range of access options through institutional or individual subscriptions, ensuring that critical research findings reach a wide audience. By fostering high-quality, peer-reviewed articles, ANNALS OF NUCLEAR MEDICINE plays a crucial role in advancing the understanding and practical application of nuclear medicine techniques, making it an essential journal for professionals and students aiming to stay at the forefront of this evolving discipline.

CLINICAL NUCLEAR MEDICINE is a premier journal dedicated to the field of nuclear medicine, published by Lippincott Williams & Wilkins. With a history of excellence since its inception in 1978, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to deepen their understanding of this rapidly evolving discipline. The journal holds a commendable Q2 ranking in both Medicine (miscellaneous) and Radiology, Nuclear Medicine and Imaging, reflecting its significant impact on advancing clinical practices and research. While currently not offered as an open-access publication, CLINICAL NUCLEAR MEDICINE ensures rigorous peer review and high-quality publications, contributing to the broad dissemination of cutting-edge studies and reviews. With its comprehensive scope encompassing both diagnostic and therapeutic nuclear medicine applications, researchers around the globe turn to this journal to stay informed and inspire innovations in patient care for the years leading up to 2024 and beyond.

The European Journal of Nuclear Medicine and Molecular Imaging is a prestigious, peer-reviewed journal published by Springer, dedicated to advancing the field of nuclear medicine and molecular imaging. With an impressive impact factor and ranked in the Q1 category for both Medicine and Radiology, Nuclear Medicine and Imaging, this journal is a pivotal platform for researchers and practitioners to disseminate significant findings from 1996 to the present, reflecting the evolution of the field. The journal boasts a notable Scopus rank, standing at #8 out of 333 in its category, placing it in the top 3% of published works, which highlights its critical importance in shaping contemporary practices and research innovations. Although it does not offer an open-access model, the journal provides various access options to ensure that important research is accessible to professionals, students, and academics alike. Through rigorous peer review and a commitment to high-quality publication, the European Journal of Nuclear Medicine and Molecular Imaging plays an essential role in the advancement of nuclear medicine, contributing to better diagnostic and therapeutic outcomes globally.

NUKLEARMEDIZIN-NUCLEAR MEDICINE is a prestigious journal published by Georg Thieme Verlag KG, focusing on pivotal advancements in the fields of Nuclear Medicine, Radiology, and Imaging. Established in 1959, this journal has served as a critical platform for disseminating innovative research, reviews, and clinical guidelines until its anticipated convergence in 2024. With an ISSN of 0029-5566 and an E-ISSN of 2567-6407, NUKLEARMEDIZIN is acknowledged in the academic community as a Q3 category journal within Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging as of 2023, highlighting its ongoing contribution to the interdisciplinary dialogue in healthcare. Although the journal does not currently offer open access, it remains accessible to professionals and students through various academic databases, ensuring that cutting-edge knowledge in this growing field is shared widely. Researchers interested in the latest methods and technologies in Nuclear Medicine will find NUKLEARMEDIZIN a valuable resource for enhancing their work and understanding the complexities of modern imaging modalities.